Combinational dual drug delivery system to enhance the care and treatment of gastric cancer patients

Xiao, Ying; Gao, Yanbin; Li, Fajuan; Deng, Zhihe

doi:10.1080/10717544.2020.1822460

Cited by 12 publications

(4 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This makes the drug prone to breakdown, reducing its activity. Therefore, a series of CPT prodrugs have been developed in order to improve the solubility and stability of CPT in aqueous solutions, including gemcitabine [ 19 ] and irinotecan [ 20 ], which have already been used in cancer chemotherapy.…”

Section: Ha-based Prodrugsmentioning

confidence: 99%

Hyaluronic Acid-Based Nanocarriers for Anticancer Drug Delivery

Cai

Chen

et al. 2023

Polymers

View full text Add to dashboard Cite

Hyaluronic acid (HA), a main component of the extracellular matrix, is widely utilized to deliver anticancer drugs due to its biocompatibility, biodegradability, non-toxicity, non-immunogenicity and numerous modification sites, such as carboxyl and hydroxyl groups. Moreover, HA serves as a natural ligand for tumor-targeted drug delivery systems, as it contains the endocytic HA receptor, CD44, which is overexpressed in many cancer cells. Therefore, HA-based nanocarriers have been developed to improve drug delivery efficiency and distinguish between healthy and cancerous tissues, resulting in reduced residual toxicity and off-target accumulation. This article comprehensively reviews the fabrication of anticancer drug nanocarriers based on HA in the context of prodrugs, organic carrier materials (micelles, liposomes, nanoparticles, microbubbles and hydrogels) and inorganic composite nanocarriers (gold nanoparticles, quantum dots, carbon nanotubes and silicon dioxide). Additionally, the progress achieved in the design and optimization of these nanocarriers and their effects on cancer therapy are discussed. Finally, the review provides a summary of the perspectives, the lessons learned so far and the outlook towards further developments in this field.

show abstract

Section: Ha-based Prodrugsmentioning

confidence: 99%

Hyaluronic Acid-Based Nanocarriers for Anticancer Drug Delivery

Cai

Chen

et al. 2023

Polymers

View full text Add to dashboard Cite

show abstract

“…One of the main problems in chemotherapy is overcoming drug resistance and improving therapy. Therefore, using dual-drug systems for combination therapy that includes various pharmaceutics with synergistic action has become a desired method [ 34 , 35 , 36 ]. There are few diverse approaches to obtaining dual-drug systems, but those based on PILs are still not well known and need extensive investigations.…”

Section: Introductionmentioning

confidence: 99%

Piperacillin/Tazobactam Co-Delivery by Micellar Ionic Conjugate Systems Carrying Pharmaceutical Anions and Encapsulated Drug

Niesyto,

Mazur,

Neugebauer

2024

Pharmaceutics

View full text Add to dashboard Cite

Previously obtained amphiphilic graft copolymers based on [2-(methacryloyloxy)ethyl]trimethylammonium chloride (TMAMA) ionic liquid were used as the matrices of three types of nanocarriers, i.e., conjugates with ionic piperacillin (PIP) and micelles with tazobactam (TAZ), which represented single systems, and dual systems bearing PIP anions and encapsulated TAZ for co-delivery. The exchange of Cl anions in TMAMA units with PIP ones resulted in a yield of 45.6–72.7 mol.%. The self-assembling properties were confirmed by the critical micelle concentration (CMC), which, after ion exchange, increased significantly (from 0.011–0.020 mg/mL to 0.041–0.073 mg/mL). The amphiphilic properties were beneficial for TAZ encapsulation to reach drug loading contents (DLCs) in the ranges of 37.2–69.5 mol.% and 50.4–80.4 mol.% and to form particles with sizes of 97–319 nm and 24–192 nm in the single and dual systems, respectively. In vitro studies indicated that the ionically conjugated drug (PIP) was released in quantities of 66–81% (7.8–15.0 μg/mL) from single-drug systems and 21–25% (2.6–3.9 μg/mL) from dual-drug systems. The release of encapsulated TAZ was more efficient, achieving 47–98% (7.5–9.0 μg/mL) release from the single systems and 47–69% (9.6–10.4 μg/mL) release from the dual ones. Basic cytotoxicity studies showed non-toxicity of the polymer matrices, while the introduction of the selected drugs induced cytotoxicity against normal human bronchial epithelial cells (BEAS-2B) with the increase in concentration.

show abstract

“…The preliminary designing of drug delivery systems provides the possibility of adjusting their physicochemical properties. There are many pathways for obtaining structures which are available to attach more than one API and can be used to prepare drug co-delivery systems with guaranteed synergistic drug action and improved treatment efficacy [ 28 , 29 , 30 ]. The dual drug systems are usually used in cancer treatment or diseases caused by drug-resistant strains, where APIs are conjugated and/or encapsulated.…”

Section: Introductionmentioning

confidence: 99%

Pharmaceutical Functionalization of Monomeric Ionic Liquid for the Preparation of Ionic Graft Polymer Conjugates

Mazur

Niesyto

Neugebauer

2022

IJMS

View full text Add to dashboard Cite

Polymerizable choline-based ionic liquid (IL), i.e., [2-(methacryloyloxy)ethyl]-trimethylammonium (TMAMA/Cl¯), was functionalized by an ion exchange reaction with pharmaceutical anions, i.e., cloxacillin (CLX¯) and fusidate (FUS¯), as the antibacterial agents. The modified biocompatible IL monomers (TMAMA/CLX¯, TMAMA/FUS¯) were copolymerized with methyl methacrylate (MMA) to prepare the graft copolymers (19–50 mol% of TMAMA units) serving as the drug (co)delivery systems. The in vitro drug release, which was driven by the exchange reaction of the pharmaceutical anions to phosphate ones in PBS medium, was observed for 44% of CLX¯ (2.7 μg/mL) and 53% of FUS¯ (3.6 μg/mL) in the single systems. Similar amounts of released drugs were detected for the dual system, i.e., 41% of CLX¯ (2.2 μg/mL) and 33% of FUS¯ (2.0 μg/mL). The investigated drug ionic polymer conjugates were examined for their cytotoxicity by MTT test, showing a low toxic effect against human bronchial epithelial cells (BEAS-2B) and normal human dermal fibroblasts (NHDF) as the normal cell lines. The satisfactory drug contents and the release profiles attained for the well-defined graft polymers with ionically bonded pharmaceuticals in the side chains make them promising drug carriers in both separate and combined drug delivery systems.

show abstract

Combinational dual drug delivery system to enhance the care and treatment of gastric cancer patients

Cited by 12 publications

References 63 publications

Hyaluronic Acid-Based Nanocarriers for Anticancer Drug Delivery

Hyaluronic Acid-Based Nanocarriers for Anticancer Drug Delivery

Piperacillin/Tazobactam Co-Delivery by Micellar Ionic Conjugate Systems Carrying Pharmaceutical Anions and Encapsulated Drug

Pharmaceutical Functionalization of Monomeric Ionic Liquid for the Preparation of Ionic Graft Polymer Conjugates

Contact Info

Product

Resources

About